adalimumab-aaty Auto-Injector 80 MG/0.8 ML and 40 MG/0.4 ML Starter Pack - Plaque Psoriasis (3 count)

RxCUI: 2668493
RxNorm name: adalimumab-aaty Auto-Injector 80 MG/0.8 ML and 40 MG/0.4 ML Starter Pack - Plaque Psoriasis (3 count)
Display name: adalimumab-aaty Auto-Injector 80 MG/0.8 ML and 40 MG/0.4 ML Starter Pack - Plaque Psoriasis (3 count)
Full name: adalimumab-aaty Auto-Injector 80 MG/0.8 ML and 40 MG/0.4 ML Starter Pack - Plaque Psoriasis (3 count)
Term type: SY
Status: DailyMed mapping
Updated: 2026-06-04 23:38:58

Purple Book Biologic Products#

BLA, Proprietary name, Proper name table
BLA	Proprietary name	Proper name	License type	Status	Latest source
761219	Yuflyma	adalimumab-aaty	351(k) Interchangeable	Rx	2026-08-01

RxNav Current And Historical NDCs#

RxNav current and historical NDC rows page 1 of 1 · 0 matching rows.

No records found.

UNII Substances#

UNII substance links page 1 of 1 · 0 matching rows.

No records found.

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
Brand	Generic	Manufacturer	SPL set ID	Effective date	Available safety fields	Join
Yuflyma	ADALIMUMAB-AATY	CELLTRION USA, Inc.	526d626f-8c9f-496c-b838-00a73bb36383	2026-07-15	Boxed warning, Warnings, Adverse reactions	Exact identifier rxcui: 2668493

DailyMed RxNorm Mappings#

unique DailyMed labels mapped to this RxNorm concept page 1 of 1 · 1 matching rows.

Set ID, RxNorm mappings, Terms table
Set ID	RxNorm mappings	Terms	SPL version	Label	Effective
526d626f-8c9f-496c-b838-00a73bb36383	{2 (0.4 ML adalimumab-aaty 100 MG/ML Auto-Injector) / 1 (0.8 ML adalimumab-aaty 100 MG/ML Auto-Injector) } Pack [GPCK] · adalimumab-aaty Auto-Injector 80 MG/0.8 ML and 40 MG/0.4 ML Starter Pack - Plaque Psoriasis (3 count) [PSN] · adalimumab-aaty Auto-Injector 80 MG/0.8 ML and 40 MG/0.4 ML Starter Pack - Plaque Psoriasis (3 count) [SY]	3	13	These highlights do not include all the information needed to use YUFLYMA safely and effectively. See full prescribing information for YUFLYMA. YUFLYMA (adalimumab-aaty) injection, for subcutaneous use Initial U.S. Approval: 2023 YUFLYMA (adalimumab-aaty) is biosimilar Biosimilar means that the biological product is approved basetd on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences betwe	20251028